Supernus Announces Positive Phase IIb Results on SPN-810 and Decision to Advance to Late Stage Development

[at noodls] – ROCKVILLE, Md., Nov. 20, 2012 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, received positive topline results from its Phase IIb study on SPN-810 … more

View todays social media effects on SUPN

View the latest stocks trending across Twitter. Click to view dashboard